5/8/2025

Elanco Animal Health's (NYSE:ELAN) stock is up by a considerable 34% over the past month. However, we wonder if the...

Source: Yahoo

5/8/2025

Elanco Animal Health ( NYSE:ELAN ) First Quarter 2025 Results Key Financial Results Revenue: US$1.19b (down 1.0% from...

Source: Yahoo

5/8/2025

Elanco Animal Health Inc (ELAN) reports robust innovation revenue and raises full-year guidance, despite facing challenges in the US retail market.

Source: Yahoo

5/8/2025

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where Elanco Animal Health Incorporated (NYSE:ELAN) stands against other Wednesday’s best-performing stocks. The stock market rebounded on Wednesday, with all major indices ending in the green as investors cheered the Federal Reserve’s decision […]

Source: Yahoo

5/7/2025

(Updates with the latest stock movement in the headline and first paragraph.) Elanco Animal Healt

Source: Yahoo

5/7/2025

Shares of animal health company Elanco (NYSE:ELAN) jumped 21.2% in the afternoon session after the company reported decent first quarter 2025 results which beat analysts' EPS expectations and included constant currency revenue outperformance. Organic sales were up 4%, thanks to strong demand in cattle health and good traction from new pet meds like Credelio Quattro. Even though sales were flat, operating margins improved, a sign they're managing prices and costs pretty well.

Source: Yahoo

5/7/2025

While the top- and bottom-line numbers for Elanco Animal Health (ELAN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Source: Yahoo

5/7/2025

The following slide deck was published by Elanco Animal Health Incorporated in conjunction with their 2025 Q1 earnings call.

Source: SeekingAlpha

5/7/2025

Elanco Animal Health Incorporated (NYSE:ELAN) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ETCompany ParticipantsTiffany Kanaga - Head of Investor...

Source: SeekingAlpha

5/7/2025

Elanco Animal Health (ELAN) delivered earnings and revenue surprises of 19.35% and 2.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Source: Yahoo

5/7/2025

Animal health company Elanco (NYSE:ELAN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.19 billion. The company’s full-year revenue guidance of $4.55 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.37 per share was 21.5% above analysts’ consensus estimates.

Source: Yahoo

5/7/2025

Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2025, provided guidance for the second quarter of 2025, and updated guidance for the full year 2025.

Source: Yahoo

5/7/2025

Food and Companionship Enriching Life ...

Source: Finnhub

5/7/2025

2025 Earnings - First Quarter May 7, 2025 3 On Today's Call Jeff Simmons Elanco Animal Health ...

Source: Finnhub

5/7/2025

Elanco Animal Health Incorporated reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported sales was USD 1,193 million compared to USD 1,205...

Source: Finnhub

5/7/2025

Elanco Animal Health Incorporated provided Earnings Guidance for the Second Quarter 2025. For the year, company expected Revenue to be in range of $1,175 Million to $1,195 Million....

Source: Finnhub

5/7/2025

Elanco Animal Health Incorporated updated Earnings Guidance for the full year 2025. For the year, company expected Revenue to be in range of $4,510 Million to $4,580 Million as compared to previous...

Source: Finnhub

5/6/2025

Animal health company Elanco (NYSE:ELAN) will be reporting results tomorrow before market hours. Here’s what to look for.

Source: Yahoo

5/5/2025

Elanco Animal Health Incorporated (NYSE:ELAN) on Monday announced the sale of certain future tiered royalties and commercial milestones associated with Xdemvy (lotilaner ophthalmic solution) 0.25% for the human health application of lotilaner to Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. The company will use the proceeds to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end o

Source: Yahoo

5/5/2025

Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. Monetization of this non-core asset will be used to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x

Source: Yahoo